Department of Gastroenterology and Metabolism, Hiroshima University Hospital, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan.
J Gastroenterol. 2019 Oct;54(10):897-906. doi: 10.1007/s00535-019-01590-w. Epub 2019 May 18.
We analyzed the influence of preceding endoscopic submucosal dissection (ESD) on the prognosis of patients with T1 colorectal carcinoma (CRC) after additional surgery using propensity-score matching.
1638 consecutive patients with T1 CRC were retrospectively identified between January 1998 and December 2016 at the Hiroshima GI Endoscopy Research Group. We assessed 602 patients with 602 T1 CRC who underwent additional surgery after ESD (n = 216) or surgery alone (n = 386). The enrolled patients were treated according to the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016, and were defined as non-endoscopically curable (non-e-curable) when they did not satisfy its curative criteria. We analyzed the pathological characteristics and the prognosis of non-e-curable patients using propensity-score matching between the additional surgery after ESD and surgery alone groups.
There were no cases of recurrence and lymph node metastasis among the e-curable patients. The rate of lymph node metastasis and recurrences in the non-e-curable patients were 10.8% and 2.6%, respectively. After propensity-score matching, there were no significant differences in the 5-year overall survival rates (96.9% vs. 92.0%), 5-year disease-free survival rates (96.7% vs. 96.7%) and 5-year disease-specific survival rates (100% vs. 98.6%) after treatment of T1 CRCs between the 2 groups in non-e-curable patients.
Preceding ESD with histological en bloc resection for patients with T1 CRC did not affect their oncologic behavior adversely after additional surgery.
本研究通过倾向评分匹配分析了先前内镜黏膜下剥离术(ESD)对 T1 结直肠癌(CRC)患者行追加手术治疗后预后的影响。
回顾性分析 1998 年 1 月至 2016 年 12 月期间 Hiroshima GI 内镜研究组收治的 1638 例 T1 CRC 患者的临床资料。本研究纳入了先前接受过 ESD 治疗(n=216)或单独手术治疗(n=386)后行追加手术治疗的 602 例 T1 CRC 患者(n=602)。根据日本结直肠癌协会(JSCCR)2016 年指南,将患者分为可内镜治疗(e-curable)和不可内镜治疗(non-e-curable)。本研究对不可内镜治疗患者的病理特征和预后进行了分析,并通过倾向评分匹配比较了 ESD 追加手术组和单独手术组患者的预后。
e-curable 患者无局部复发和淋巴结转移。non-e-curable 患者的淋巴结转移率和复发率分别为 10.8%和 2.6%。经倾向评分匹配后,non-e-curable 患者的 5 年总生存率(96.9% vs. 92.0%)、5 年无病生存率(96.7% vs. 96.7%)和 5 年疾病特异性生存率(100% vs. 98.6%)在 ESD 追加手术组和单独手术组间差异均无统计学意义。
对 T1 CRC 患者行整块切除的 ESD 治疗并不会对其追加手术治疗后的肿瘤学行为产生不利影响。